ea0049ep607 | Diabetes therapy | ECE2017
Sedman Tuuli
, Krass Maarja
, Runkorg Kertu
, Vasar Eero
, Volke Vallo
Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have become a popular tool for the treatment of type 2 diabetes. Unlike many other antidiabetic drug classes, distinct GLP-1 RAs have different therapeutic profiles, mostly due to their different pharmacokinetic properties. Animal experiments and human data indicate that tolerance develops toward at least some of their effects, e.g., gastric motility. Whether tolerance develops toward the glucose-lowering effect...